Transcode Therapeutics, Inc. (NASDAQ:RNAZ)
| Market Cap | 1.82M-88.1% |
| Revenue (ttm) | 0 |
| Net Income | -42.78M-73.9% |
| EPS | -50.69+48.6% |
| Shares Out | 1.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,412.971 |
| Open | 1.80 |
| Previous Close | 1.76 |
| Day's Range | 1.68 - 1.80 |
| 52-Week Range | 1.52 - 15.94 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 18, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About RNAZ
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
$RNAZ stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RNAZ holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RNAZ's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RNAZ Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RNAZ patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RNAZ from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RNAZ
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $1.05K |
Estimated from each fund’s disclosed top holdings × AUM
RNAZ Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RNAZ’s recent data — informational, not investment advice